Panelists in this video:
+ Mr Suveer Shrivastava, Global Pharma Compliance Expert (Moderator)
+ Mr Amit Malviya, VP-Quality Assurance, Zest Pharma
+ Mr Mahanand Thakur, VP-Operations, McW Healthcare
+ Ms Shilpy Singh, GM & Head-Project Management, Piramal Pharma
+ Mr Vikalp Nagori, Associate Director – Formulation Technology Transfer, Cipla
Key Highlights:
[1] The future of Indian pharma lies beyond generics — in innovation, biosimilars, peptides, and globally competitive drug development driven by skill, collaboration and continuous research.
[2] Innovation must be purposeful and patient-focused. Proof of concept is critical to ensure innovation addresses real and underserved healthcare needs.
[3] Regulatory support from regulatory bodies like CDSCO is vital to create an ecosystem that encourages entrepreneurship, innovation and talent retention.
[4] AI and automation are no longer optional for pharma. They are essential to build transparency, improve compliance, reduce manual dependency, and prepare the industry for the future.
[5] Ethical practices, accountability, quality culture, and patient-centricity will define India’s long-term credibility and global reputation in pharma.
[6] A proactive approach to innovation, capability building and future-ready manufacturing will determine India’s leadership in the global pharma landscape.